CO6210806A2 - Composiciones con forma de dosificacion simple para liberar multiples farmacos a diferentes velocidades de liberacion - Google Patents
Composiciones con forma de dosificacion simple para liberar multiples farmacos a diferentes velocidades de liberacionInfo
- Publication number
- CO6210806A2 CO6210806A2 CO09070672A CO09070672A CO6210806A2 CO 6210806 A2 CO6210806 A2 CO 6210806A2 CO 09070672 A CO09070672 A CO 09070672A CO 09070672 A CO09070672 A CO 09070672A CO 6210806 A2 CO6210806 A2 CO 6210806A2
- Authority
- CO
- Colombia
- Prior art keywords
- tablet
- weight
- layer
- component
- central
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
1.- Una composición de tableta en tableta, caracterizada porque comprende: a) una tableta central que comprende; uno o más estrógenos; un componente rellenador/diluyente central que comprende de aproximadamente 30% a aproximadamente 85% en peso de la tableta central; un componente rellenador/aglomerante central que comprende de aproximadamente 1% a aproximadamente 30% en peso la tableta central; un componente polimérico de formación de gel hidrofílico central que comprende de aproximadamente 1% a aproximadamente 40% en peso de la tableta central; yopcionalmente, un componente lubricante central que comprende de aproximadamente 0.01% a aproximadamente 2% en peso de la tableta central; y b) una capa de tableta exterior comprimida que comprende:uno o más agentes terapéuticos seleccionados del grupo consiste de modulador del receptor de estrógeno selectivos y agentes progestacionales; un componente rellenador/diluyente de la capa exterior que comprende de aproximadamente 10% a aproximadamente 80% en peso de la capa de la tableta exterior comprimida; un componente rellenador/aglomerante de la capa exterior que comprende de aproximadamente 1% a aproximadamente 60% peso de la capa de la tableta exterior comprimida; un componente de polímero de formación de gel hidrofílico de la capa exterior que comprende de aproximadamente 1%- a aproximadamente 70% en peso de la capa la tableta exterior comprimida; opcionalmente, un componente antioxidante que comprende aproximadamente 0.01% a aproximadamente 4% en peso de la capa de la tableta exterior comprimida; yopcionalmente, un componente lubricante de la capa exterior que comprende de aproximadamente 0.01% a aproximadamente 2% en peso de la capa de la tableta exterior comprimida.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88480107P | 2007-01-12 | 2007-01-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6210806A2 true CO6210806A2 (es) | 2010-10-20 |
Family
ID=39315069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO09070672A CO6210806A2 (es) | 2007-01-12 | 2009-07-08 | Composiciones con forma de dosificacion simple para liberar multiples farmacos a diferentes velocidades de liberacion |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20080175908A1 (es) |
| EP (1) | EP2117518A2 (es) |
| JP (1) | JP2010515758A (es) |
| KR (1) | KR20090104862A (es) |
| CN (1) | CN101631536A (es) |
| AR (1) | AR064875A1 (es) |
| AU (1) | AU2008206476A1 (es) |
| BR (1) | BRPI0806543A2 (es) |
| CL (1) | CL2008000095A1 (es) |
| CO (1) | CO6210806A2 (es) |
| IL (1) | IL199656A0 (es) |
| MX (1) | MX2009007254A (es) |
| PE (1) | PE20081632A1 (es) |
| RU (1) | RU2009125413A (es) |
| TW (1) | TW200836773A (es) |
| WO (1) | WO2008089087A2 (es) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006084058A2 (en) | 2005-02-03 | 2006-08-10 | The General Hospital Corporation | Method for treating gefitinib resistant cancer |
| WO2007056118A1 (en) | 2005-11-04 | 2007-05-18 | Wyeth | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
| SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| EP2915532B1 (en) | 2008-06-17 | 2016-10-19 | Wyeth LLC | Antineoplastic combinations containing hki-272 and vinorelbine |
| US20090324714A1 (en) * | 2008-06-27 | 2009-12-31 | Wyeth | Dual adhesive technology |
| ES2614912T3 (es) | 2008-08-04 | 2017-06-02 | Wyeth Llc | Combinaciones antineoplásicas de 4-anilino-3-cianoquinolinas y capecitabina |
| EP3000467B1 (en) | 2009-04-06 | 2023-03-01 | Wyeth LLC | Treatment regimen utilizing neratinib for breast cancer |
| US20110217369A1 (en) * | 2009-09-03 | 2011-09-08 | Ranbaxy Laboratories Limited | Fenofibrate compositions |
| WO2011056532A2 (en) | 2009-10-27 | 2011-05-12 | Wyeth Llc | Bazedoxifene formulations with antioxidants |
| HUE046606T2 (hu) * | 2009-11-09 | 2020-03-30 | Wyeth Llc | Neratinib maleát tabletta formái |
| CN102724962B (zh) | 2009-11-09 | 2017-05-17 | 惠氏有限责任公司 | 包衣药物球状体及其用于消除或减少病症比如呕吐和腹泻的用途 |
| US20110280936A1 (en) * | 2010-05-17 | 2011-11-17 | Aptapharma, Inc. | Self Breaking Tablets |
| PL2826467T3 (pl) | 2010-12-22 | 2018-01-31 | Purdue Pharma Lp | Zamknięte, zabezpieczone przed manipulowaniem formy dozowania o kontrolowanym uwalnianiu |
| ES2581323T3 (es) | 2010-12-23 | 2016-09-05 | Purdue Pharma Lp | Formas de dosificación oral sólida resistentes a alteraciones |
| CA2835979C (en) | 2011-06-01 | 2018-05-01 | Estetra S.A. | Process for the production of estetrol intermediates |
| PL2714710T3 (pl) | 2011-06-01 | 2017-03-31 | Estetra S.P.R.L. | Sposób wytwarzania estetrolowych związków pośrednich |
| EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
| ES2885523T3 (es) | 2011-11-23 | 2021-12-14 | Therapeuticsmd Inc | Formulaciones y terapias de reposición hormonal de combinación naturales |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| EP2875830A4 (en) | 2012-07-20 | 2016-02-24 | Otsuka Pharma Co Ltd | TABLET HAVING DRY INK FILM ON THE SURFACE THEREOF, AND INK FOR INKJET PRINTER |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
| MX369035B (es) * | 2013-12-12 | 2019-10-25 | Donesta Bioscience B V | Unidad de dosificacion solida de disolucion oral que contiene un componente de estetrol. |
| RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
| CN104013630B (zh) * | 2014-05-23 | 2018-08-21 | 合肥九研医药科技开发有限公司 | 一种复方醋酸巴多昔芬雌激素组合物 |
| JP2017523138A (ja) | 2014-07-29 | 2017-08-17 | セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． | 経皮クリーム |
| CN104546794A (zh) * | 2015-01-05 | 2015-04-29 | 万特制药(海南)有限公司 | 一种醋酸巴多昔芬胶囊及其制备方法 |
| SI3310345T1 (sl) | 2015-06-18 | 2021-05-31 | Estetra Sprl | Orodisperzibilna tableta, ki vsebuje estetrol |
| MY195019A (en) | 2015-06-18 | 2023-01-03 | Estetra Sprl | Orodispersible dosage unit containing an estetrol component |
| RS61777B1 (sr) | 2015-06-18 | 2021-06-30 | Estetra Sprl | Oralno-disperzibilna tableta koja sadrži estetrol |
| ME03728B (me) | 2015-06-18 | 2021-01-20 | Estetra Sprl | Orodisperzibilna dozna jedinica koja sadrži komponentu estetrola |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| KR101893110B1 (ko) * | 2016-07-27 | 2018-08-31 | 삼일제약 주식회사 | 비페닐디메틸디카르복실레이트 및 마늘유를 포함하는 제제 |
| KR20220144885A (ko) | 2016-08-05 | 2022-10-27 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
| JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| CN111067907A (zh) * | 2018-10-18 | 2020-04-28 | 常州大学 | 孕激素在抑制血管内皮生长因子表达中的应用 |
| KR102372271B1 (ko) * | 2020-01-03 | 2022-03-10 | 주식회사 서흥 | 천연 소재에 기반한 정제 조성물 및 정제 |
| CN115989023A (zh) * | 2020-08-25 | 2023-04-18 | 艾伯维公司 | 多药物递送的系统和方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2565115A (en) * | 1948-10-28 | 1951-08-21 | Squibb & Sons Inc | Method of obtaining a conjugated estrogen preparation |
| US2720483A (en) * | 1951-02-21 | 1955-10-11 | Olin Mathieson | Method of obtaining a conjugatedestrogen preparation |
| US5210081A (en) * | 1992-02-26 | 1993-05-11 | American Home Products Corporation | Alkali metal 8,9-dehydroestrone sulfate esters |
| US5554601A (en) * | 1993-11-05 | 1996-09-10 | University Of Florida | Methods for neuroprotection |
| US5998402A (en) * | 1996-04-19 | 1999-12-07 | American Home Products Corporation | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
| US6372254B1 (en) * | 1998-04-02 | 2002-04-16 | Impax Pharmaceuticals Inc. | Press coated, pulsatile drug delivery system suitable for oral administration |
| US6479535B1 (en) * | 1998-05-15 | 2002-11-12 | Wyeth | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations |
| CA2566771A1 (en) * | 2004-06-07 | 2005-12-22 | Wyeth | Sugar coatings and methods therefor |
| AR054806A1 (es) * | 2005-06-29 | 2007-07-18 | Wyeth Corp | Formulaciones de estrogenos conjugados y bazedoxifeno |
| EP2086550A2 (en) * | 2006-11-29 | 2009-08-12 | Wyeth | Estrogen/ serm and estrogen/ progestin bi-layer tablets |
-
2008
- 2008-01-11 TW TW097101166A patent/TW200836773A/zh unknown
- 2008-01-11 US US12/013,109 patent/US20080175908A1/en not_active Abandoned
- 2008-01-11 EP EP08727602A patent/EP2117518A2/en not_active Withdrawn
- 2008-01-11 MX MX2009007254A patent/MX2009007254A/es not_active Application Discontinuation
- 2008-01-11 AU AU2008206476A patent/AU2008206476A1/en not_active Abandoned
- 2008-01-11 PE PE2008000126A patent/PE20081632A1/es not_active Application Discontinuation
- 2008-01-11 AR ARP080100140A patent/AR064875A1/es unknown
- 2008-01-11 WO PCT/US2008/050899 patent/WO2008089087A2/en active Application Filing
- 2008-01-11 KR KR1020097016863A patent/KR20090104862A/ko not_active Application Discontinuation
- 2008-01-11 BR BRPI0806543-8A2A patent/BRPI0806543A2/pt not_active IP Right Cessation
- 2008-01-11 CL CL200800095A patent/CL2008000095A1/es unknown
- 2008-01-11 CN CN200880007862A patent/CN101631536A/zh active Pending
- 2008-01-11 RU RU2009125413/15A patent/RU2009125413A/ru not_active Application Discontinuation
- 2008-01-11 JP JP2009545710A patent/JP2010515758A/ja active Pending
-
2009
- 2009-07-02 IL IL199656A patent/IL199656A0/en unknown
- 2009-07-08 CO CO09070672A patent/CO6210806A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008089087A3 (en) | 2009-06-25 |
| JP2010515758A (ja) | 2010-05-13 |
| CN101631536A (zh) | 2010-01-20 |
| EP2117518A2 (en) | 2009-11-18 |
| IL199656A0 (en) | 2010-04-15 |
| AU2008206476A1 (en) | 2008-07-24 |
| KR20090104862A (ko) | 2009-10-06 |
| AR064875A1 (es) | 2009-04-29 |
| TW200836773A (en) | 2008-09-16 |
| BRPI0806543A2 (pt) | 2014-04-22 |
| RU2009125413A (ru) | 2011-02-20 |
| PE20081632A1 (es) | 2008-12-10 |
| MX2009007254A (es) | 2009-08-12 |
| CL2008000095A1 (es) | 2008-05-16 |
| US20080175908A1 (en) | 2008-07-24 |
| WO2008089087A2 (en) | 2008-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6210806A2 (es) | Composiciones con forma de dosificacion simple para liberar multiples farmacos a diferentes velocidades de liberacion | |
| BR112018009060A8 (pt) | composição de revestimento de semente | |
| WO2008122965A3 (en) | Pharmaceutical cyclosporin compositions | |
| ES2556585T3 (es) | Composiciones que comprenden sulfato de salbutamol | |
| BRPI0615860B8 (pt) | composição farmacêutica de liberação prolongada monolítica sólida | |
| PE20081301A1 (es) | Tabletas de bi-capa de estrogeno/moduladores selectivos de receptores de estrogeno (serm) y estrogeno/progestina | |
| MX2019003544A (es) | Composiciones que comprenden un ligando de union al receptor cannabinoide. | |
| MX2014011815A (es) | Composiciones farmaceuticas de liberacion inmediata con propiedades disuasivas de abuso. | |
| EA201290984A1 (ru) | Гелеобразные фармацевтические композиции, препятствующие злоупотреблению | |
| UY31698A (es) | Preparacion solida de desintegracion oral | |
| BR112014011841A2 (pt) | material de entrega de fármacos hidrofóbicos, método para a produção do mesmo e métodos para a entrega de uma composição de entrega de fármacos | |
| CL2013001338A1 (es) | Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih. | |
| MX356111B (es) | Composiciones farmaceuticas disuasorias de abuso, de liberacion inmediata. | |
| BR112014031914A2 (pt) | cápsula de estradiol solúvel para inserção vaginal | |
| AR095672A1 (es) | Composiciones farmacéuticas que comprenden everolimus | |
| AR082998A1 (es) | Asociacion farmaceutica para tratar y/o prevenir mioma y/o endometriosis, uso de resveratrol y progestogeno, composicion farmaceutica para tratamiento y/o prevencion de mioma y/o endometriosis, medicamento para tratamiento y/o prevencion de mioma y/o endometriosis, kit y metodo para tratamiento y/o prevencion de mioma y/o endometriosis | |
| MX2011000884A (es) | Medicamento apetecible de administracion oral bajo forma solida. | |
| CL2009000368A1 (es) | 3-(amido o sulfamido)-4-(4-azinil sustituido) benzamidas o benzosulfonamidas; la composicion farmaceutica que los contiene; el uso de los compuestos; y un kit que contiene dichos compeustos; utiles como inhibidores del receptor de quimioquinas cxcr3. | |
| BR112013009153A2 (pt) | formulação de ligante de fosfato para dosagem única. | |
| UY30215A1 (es) | Derivados de cromanol sustituidos, procedimientos para su preparacion, composiciones farmacéuticas que los contienen y aplicaciones | |
| BR112015017246A8 (pt) | composição farmacêutica aquosa, seu uso e seringa | |
| ES2528366T3 (es) | Citicolina para el tratamiento del glaucoma | |
| BRPI1014067A8 (pt) | Uso de pelo menos uma aziridina, composição, formulação de agente aglutinante, uso da composição, e materiais técnicos | |
| CL2008000728A1 (es) | Composicion anestesica para la administracion topica que comprende un agente anestesico local en nanoparticulas polimericas y por lo menos un agente que aumenta la viscosidad. | |
| PH12016500693B1 (en) | Slow-release solid oral compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |